Intermittent Preventive Treatment of Malaria in Pregnancy with Mefloquine in HIV-Negative Women: A Multicentre Randomized Controlled Trial

English version České info

Background:
Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended by WHO to prevent malaria in African pregnant women. The spread of SP parasite resistance has raised concerns regarding long-term use for IPT. Mefloquine (MQ) is the most promising of available alternatives to SP based on safety profile, long half-life, and high efficacy in Africa. We evaluated the safety and efficacy of MQ for IPTp compared to those of SP in HIV-negative women.

Methods and Findings:
A total of 4,749 pregnant women were enrolled in an open-label randomized clinical trial conducted in Benin, Gabon, Mozambique, and Tanzania comparing two-dose MQ or SP for IPTp and MQ tolerability of two different regimens. The study arms were: (1) SP, (2) single dose MQ (15 mg/kg), and (3) split-dose MQ in the context of long lasting insecticide treated nets. There was no difference on low birth weight prevalence (primary study outcome) between groups (360/2,778 [13.0%]) for MQ group and 177/1,398 (12.7%) for SP group; risk ratio [RR], 1.02 (95% CI 0.86–1.22; p = 0.80 in the ITT analysis). Women receiving MQ had reduced risks of parasitemia (63/1,372 [4.6%] in the SP group and 88/2,737 [3.2%] in the MQ group; RR, 0.70 [95% CI 0.51–0.96]; p = 0.03) and anemia at delivery (609/1,380 [44.1%] in the SP group and 1,110/2743 [40.5%] in the MQ group; RR, 0.92 [95% CI 0.85–0.99]; p = 0.03), and reduced incidence of clinical malaria (96/551.8 malaria episodes person/year [PYAR] in the SP group and 130/1,103.2 episodes PYAR in the MQ group; RR, 0.67 [95% CI 0.52–0.88]; p = 0.004) and all-cause outpatient attendances during pregnancy (850/557.8 outpatients visits PYAR in the SP group and 1,480/1,110.1 visits PYAR in the MQ group; RR, 0.86 [0.78–0.95]; p = 0.003). There were no differences in the prevalence of placental infection and adverse pregnancy outcomes between groups. Tolerability was poorer in the two MQ groups compared to SP. The most frequently reported related adverse events were dizziness (ranging from 33.9% to 35.5% after dose 1; and 16.0% to 20.8% after dose 2) and vomiting (30.2% to 31.7%, after dose 1 and 15.3% to 17.4% after dose 2) with similar proportions in the full and split MQ arms. The open-label design is a limitation of the study that affects mainly the safety assessment.

Conclusions:
Women taking MQ IPTp (15 mg/kg) in the context of long lasting insecticide treated nets had similar prevalence rates of low birth weight as those taking SP IPTp. MQ recipients had less clinical malaria than SP recipients, and the pregnancy outcomes and safety profile were similar. MQ had poorer tolerability even when splitting the dose over two days. These results do not support a change in the current IPTp policy.

Trial registration:
ClinicalTrials.gov NCT 00811421; Pan African Clinical Trials Registry PACTR 2010020001429343

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Intermittent Preventive Treatment of Malaria in Pregnancy with Mefloquine in HIV-Negative Women: A Multicentre Randomized Controlled Trial. PLoS Med 11(9): e32767. doi:10.1371/journal.pmed.1001733
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001733

Souhrn

Trial registration:
ClinicalTrials.gov NCT 00811421; Pan African Clinical Trials Registry PACTR 2010020001429343

Please see later in the article for the Editors' Summary

Zdroje

1. MenendezC, OrdiJ, IsmailMR, VenturaPJ, AponteJJ, et al. (2000) The impact of placental malaria on gestational age and birth weight. J Infect Dis 181: 1740–1745.

2. SchwarzNG, AdegnikaAA, BreitlingLP, GaborJ, AgnandjiST, et al. (2008) Placental malaria increases malaria risk in the first 30 months of life. Clin Infect Dis 47: 1017–1025.

3. DesaiM, ter KuileFO, NostenF, McGreadyR, AsamoaK, et al. (2007) Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 7: 93–104.

4. BrabinBJ (1983) An analysis of malaria in pregnancy in Africa. Bull World Health Organ 61: 1005–1016.

5. MenendezC, D'AlessandroU, ter KuileFO (2007) Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect Dis 7: 126–135.

6. WHO (2004) A strategic framework for malaria prevention and control during pregnancy in the African region. AFR/MAL/04/01. Geneva: World Health Organization.

7. WHO (2012) Intermittent Preventive Treatment of malaria in pregnancy using Sulfadoxine-Pyrimethamine (IPTp-SP). Updated WHO Policy Recommendation. Geneva: WHO. Available: http://www.who.int/malaria/iptp_sp_updated_policy_recommendation_en_102012.pdf

8. WHO (2005) Technical Consultation on Malaria and HIV Interactions and Public Health Policy Implications (2004). Malaria and HIV interactions and their implications for public health policy. Geneva: WHO.

9. MenendezC, BardajiA, SigauqueB, RomagosaC, SanzS, et al. (2008) A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic. PLoS ONE 3: e1934.

10. SicuriE, BardajiA, NhampossaT, MaixenchsM, NhacoloA, et al. (2010) Cost-effectiveness of intermittent preventive treatment of malaria in pregnancy in southern Mozambique. PLoS ONE 5: e13407.

11. ter KuileFO, van EijkAM, FillerSJ (2007) Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA 297: 2603–2616.

12. SeveneE, GonzalezR, MenendezC (2010) Current knowledge and challenges of antimalarial drugs for treatment and prevention in pregnancy. Expert Opin Pharmacother 11: 1277–1293.

13. WardSA, SeveneEJ, HastingsIM, NostenF, McGreadyR (2007) Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis 7: 136–144.

14. RamharterM, WernsdorferWH, KremsnerPG (2004) In vitro activity of quinolines against Plasmodium falciparum in Gabon. Acta Trop 90: 55–60.

15. UhlemannAC, RamharterM, LellB, KremsnerPG, KrishnaS (2005) Amplification of Plasmodium falciparum multidrug resistance gene 1 in isolates from Gabon. J Infect Dis 192: 1830–1835.

16. FDA (2008) Department of Health and Human Services Food and Drug Administration 21 CFR part 201 [Docket number FDA–2006–N–0515] (Formerly docket number 2006N–0467) RIN 0910–AF11 Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Available: http://wwwgpogov/fdsys/pkg/FR-2008-05-29/pdf/E8-11806pdf

17. AubouyA, FievetN, BertinG, SagboJC, KossouH, et al. (2007) Dramatically decreased therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine, but not mefloquine, in southern Benin. Trop Med Int Health 12: 886–894.

18. CDC (2011) Update: new recommendations for mefloquine use in pregnancy. Available: http://www.cdc.gov/malaria/new_info/2011/mefloquine_pregnancy.html Accessed 31 July 2013

19. McGreadyR, ChoT, HkirijaroenL, SimpsonJ, ChongsuphajaisiddhiT, et al. (1998) Quinine and mefloquine in the treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy. Ann Trop Med Parasitol 92: 643–653.

20. ter KuileFO, NostenF, LuxemburgerC, KyleD, Teja-IsavatharmP, et al. (1995) Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bull World Health Organ 73: 631–642.

21. NostenF, VincentiM, SimpsonJ, YeiP, ThwaiKL, et al. (1999) The effects of mefloquine treatment in pregnancy. Clin Infect Dis 28: 808–815.

22. SteketeeRW, WirimaJJ, HightowerAW, SlutskerL, HeymannDL, et al. (1996) The effect of malaria and malaria prevention in pregnancy on offspring birthweight, prematurity, and intrauterine growth retardation in rural Malawi. Am J Trop Med Hyg 55: 33–41.

23. BriandV, BotteroJ, NoelH, MasseV, CordelH, et al. (2009) Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. J Infect Dis 200: 991–1001.

24. Denoeud-NdamL, ClementMC, BriandV, AkakpoJ, AgossouVK, et al. (2012) Tolerability of mefloquine intermittent preventive treatment for malaria in HIV-infected pregnant women in Benin. J Acquir Immune Defic Syndr 61: 64–72.

25. Le PortA, CottrellG, DechavanneC, BriandV, BouraimaA, et al. (2011) Prevention of malaria during pregnancy: assessing the effect of the distribution of IPTp through the national policy in Benin. Am J Trop Med Hyg 84: 270–275.

26. GonzálezR, DesaiM, MaceteE, OumaP, KakolwaMA, et al. (2014) Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-infected women receiving cotrimoxazole prophylaxis: a multicenter randomized placebo-controlled trial. PLoS Med 11: e1001733.

27. BallardJL, KhouryJC, WedigK, WangL, Eilers-WalsmanBL, et al. (1991) New Ballard Score, expanded to include extremely premature infants. J Pediatr 119: 417–423.

28. GreenwoodAM, ArmstrongJR, ByassP, SnowRW, GreenwoodBM (1992) Malaria chemoprophylaxis, birth weight and child survival. Trans R Soc Trop Med Hyg 86: 483–485.

29. SwysenC, VekemansJ, BrulsM, OyakhiromeS, DrakeleyC, et al. (2011) Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. Malar J 10: 223.

30. PlancheT, KrishnaS, KombilaM, EngelK, FaucherJF, et al. (2001) Comparison of methods for the rapid laboratory assessment of children with malaria. Am J Trop Med Hyg 65: 599–602.

31. OrdiJ, IsmailMR, VenturaPJ, KahigwaE, HirtR, et al. (1998) Massive chronic intervillositis of the placenta associated with malaria infection. Am J Surg Pathol 22: 1006–1011.

32. IsmailMR, OrdiJ, MenendezC, VenturaPJ, AponteJJ, et al. (2000) Placental pathology in malaria: a histological, immunohistochemical, and quantitative study. Hum Pathol 31: 85–93.

33. RogersonSJ, MkundikaP, KanjalaMK (2003) Diagnosis of Plasmodium falciparum malaria at delivery: comparison of blood film preparation methods and of blood films with histology. J Clin Microbiol 41: 1370–1374.

34. ZouG (2004) A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159: 702–706.

35. EMEA (2000) Points to consider on switching between superiority and non-inferiority. The European Agency for the Evaluation of Medicinal Products Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003658.pdf.

36. BardajiA, SigauqueB, BruniL, RomagosaC, SanzS, et al. (2008) Clinical malaria in African pregnant women. Malar J 7: 27.

37. WHO (2000) Safety Monitoring of Medicinal Products. Guidelines for setting up and running a Pharmacovigilance Centre Uppsala Monitoring Centre: WHO ISBN 91-630-9004-X.

38. BriandV, DenoeudL, MassougbodjiA, CotM (2008) Efficacy of intermittent preventive treatment versus chloroquine prophylaxis to prevent malaria during pregnancy in Benin. J Infect Dis 198: 594–601.

39. NostenF, ter KuileF, MaelankiriL, ChongsuphajaisiddhiT, NopdonrattakoonL, et al. (1994) Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis 169: 595–603.

40. AlonsoPL, LindsaySW, Armstrong SchellenbergJR, KeitaK, GomezP, et al. (1993) A malaria control trial using insecticide-treated bed nets and targeted chemoprophylaxis in a rural area of The Gambia, west Africa. 6. The impact of the interventions on mortality and morbidity from malaria. Trans R Soc Trop Med Hyg 87 Suppl 2: 37–44.

41. SchlagenhaufP, BlumentalsWA, SuterP, RegepL, Vital-DurandG, et al. (2012) Pregnancy and fetal outcomes after exposure to mefloquine in the pre- and periconception period and during pregnancy. Clin Infect Dis 54: e124–131.

42. VanhauwereB, MaraditH, KerrL (1998) Post-marketing surveillance of prophylactic mefloquine (Lariam) use in pregnancy. Am J Trop Med Hyg 58: 17–21.

43. LobelHO, MianiM, EngT, BernardKW, HightowerAW, et al. (1993) Long-term malaria prophylaxis with weekly mefloquine. Lancet 341: 848–851.

44. SchlagenhaufP (1999) Mefloquine for malaria chemoprophylaxis 1992–1998: a review. J Travel Med 6: 122–133.

45. SchlagenhaufP, AdamcovaM, RegepL, SchaererMT, RheinHG (2010) The position of mefloquine as a 21st century malaria chemoprophylaxis. Malar J 9: 357.

46. SteffenR, FuchsE, SchildknechtJ, NaefU, FunkM, et al. (1993) Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 341: 1299–1303.

47. GonzalezR, HellgrenU, GreenwoodB, MenendezC (2014) Mefloquine safety and tolerability in pregnancy: a systematic literature review. Malar J 13: 75.

48. SteketeeRW, WirimaJJ, SlutskerL, KhoromanaCO, HeymannDL, et al. (1996) Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Am J Trop Med Hyg 55: 50–56.

49. MakasaM, FylkesnesK, MicheloC, KayeyiN, ChirwaB, et al. (2012) Declining syphilis trends in concurrence with HIV declines among pregnant women in Zambia: observations over 14 years of national surveillance. Sex Transm Dis 39: 173–181.

50. ChicoRM, ChandramohanD (2011) Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy. Expert Opin Drug Metab Toxicol 7: 1153–1167.

51. NevinRL (2012) Limitations of postmarketing surveillance in the analysis of risk of pregnancy loss associated with maternal mefloquine exposure. Clin Infect Dis 55: 1167–1168 author reply 1168–1169.

52. MPAC (2013) Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2013 meeting. Malar J 12: 456.